Cargando…
LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
BACKGROUND: Vaccination strategies that provide enhanced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are needed. We evaluated the safety and immunogenicity of a bivalent omicron containing vaccine, mRNA-1273.214 (50 µg), administered as a second booster dos...
Autores principales: | Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R, Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne, Chen, Xing, Chang, Ying, Sutherland, Andrea, Montefiori, David, Girard, Bethany, Edwards, Darin, Feng, Jing, Zhou, Honghong, Baden, Lindsey R, Miller, Jacqueline, Das, Rituparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752807/ http://dx.doi.org/10.1093/ofid/ofac492.1873 |
Ejemplares similares
-
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023) -
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
por: Chalkias, Spyros, et al.
Publicado: (2023) -
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)